Depemokimab (GSK3511294)

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

Nasal Polyps

Phase 3

Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps

CompletedNCT05274750

GlaxoSmithKlineNasal Polyps

Start: 2022-04-22End: 2024-08-27Updated: 2025-12-03

Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)

CompletedNCT05281523

GlaxoSmithKlineNasal Polyps

Start: 2022-04-18End: 2024-08-06Updated: 2025-09-09

Related Papers

Population Pharmacokinetics and Pharmacodynamics of Depemokimab in People with Asthma and Chronic Rhinosinusitis with Nasal Polyps

The Journal of Clinical Pharmacology2026-07-30

Safety and Tolerability of Twice-Yearly Depemokimab in Patients with Asthma and Chronic Rhinosinusitis with Nasal Polyps: Pooled Results from SWIFT-1/-2 and ANCHOR-1/-2.

2025-12-29

Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials.

2025-03-0120 citations